CAS: 1286279-29-5
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | BMS-813160 REF: 54-BUP08645CAS: 1286279-29-5 | ≥98% | 510.00 €~2,226.00 € | Wed 30 Apr 25 |
 | BMS-813160 REF: TM-T4584CAS: 1286279-29-5 | 99.66% - 99.78% | 63.00 €~1,644.00 € | Tue 06 May 25 |
 | BMS 813160 REF: 3D-BB164193CAS: 1286279-29-5 | Min. 95% | 331.00 €~1,581.00 € | Tue 10 Jun 25 |
Ref: 54-BUP08645
| 25mg | 510.00 € | ||
| 50mg | 833.00 € | ||
| 100mg | 1,188.00 € | ||
| 500mg | 2,226.00 € |
Estimated delivery in United States, on Wednesday 30 Apr 2025
BMS-813160
CAS:1286279-29-5
BMS-813160 is the first dual CCR2/CCR5 antagonist to enter Clinical development for cardiovascular.
Formula:
C25H40N8O2
Purity:
99.66% - 99.78%
Color and Shape:
Solid
Molecular weight:
484.64
Ref: TM-T4584
| 1mg | 63.00 € | ||
| 5mg | 137.00 € | ||
| 10mg | 187.00 € | ||
| 25mg | 341.00 € | ||
| 50mg | 567.00 € | ||
| 100mg | 810.00 € | ||
| 500mg | 1,644.00 € | ||
| 1mL*10mM (DMSO) | 145.00 € |
Estimated delivery in United States, on Tuesday 6 May 2025
BMS 813160
CAS:1286279-29-5
Antagonist of chemokine receptors CCR2 and CCR5
Formula:
C25H40N8O2
Purity:
Min. 95%
Molecular weight:
484.64 g/mol
Ref: 3D-BB164193
| 1mg | 331.00 € | ||
| 5mg | 1,049.00 € | ||
| 10mg | 1,581.00 € |
Estimated delivery in United States, on Tuesday 10 Jun 2025
